Urology News and Research

Latest Urology News and Research

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

4 Apr 2014

Actavis opens new regional headquarters in Singapore

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region.

3 Apr 2014

Actavis announces acquisition of Silom Medical for $100 million

Actavis plc, a leading global specialty pharmaceutical company today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash.

1 Apr 2014

Antimuscarinics plus α-blockers ‘recommended for male LUTS’

Antimuscarinics “could and should” be used in the pharmacological treatment of men with lower urinary tract symptoms caused by benign prostatic hyperplasia or bladder outlet obstruction, say the authors of a meta-analysis published in Urology.

31 Mar 2014

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent).

29 Mar 2014

Scientists move a step closer to preserving fertility in young boys with cancer

Scientists have moved a step closer to being able to preserve fertility in young boys who undergo chemotherapy and radiation treatments for cancer. The new research, published in Fertility and Sterility, the journal of the American Society for Reproductive Medicine, addresses the safety of an option scientists are developing for boys who aren't sexually mature and cannot bank sperm.

28 Mar 2014

PatientPoint signs distribution agreement with HealthTronics IT Solutions for urology technology

PatientPoint announced today that they have entered into a distribution agreement with HealthTronics IT Solutions to deliver population health management solutions within urology to drive improved adherence and compliance.

25 Mar 2014

Prostate stiffness is a risk factor for voiding dysfunction

Prostate elasticity is an independent risk factor for urinary voiding symptoms, although not for lower urinary tract symptoms in general or storage symptoms, clinical research indicates.

24 Mar 2014

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).

24 Mar 2014

Renal mass biopsy rates increasing in kidney cancer

Rates of renal mass biopsy have been historically low in patients with kidney cancer, but are steadily rising, shows an analysis of Medicare data.

19 Mar 2014

Ipsen: Dysport Phase IIa clinical trial effective in treatment of NDO

Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced positive results from its phase IIa clinical trial assessing Dysport in the treatment of Neurogenic Detrusor Overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics.

19 Mar 2014

Engineers design modified lens to improve efficiency of lithotripsy

Duke engineers have devised a way to improve the efficiency of lithotripsy -- the demolition of kidney stones using focused shock waves. After decades of research, all it took was cutting a groove near the perimeter of the shock wave-focusing lens and changing its curvature.

19 Mar 2014

UL researcher receives €250,000 to investigate Benign Prostatic Hyperplasia

University of Limerick researcher, Dr Niall Kelly was recently awarded in the region of €250,000 by the Health Research Board to investigate a condition called Benign Prostatic Hyperplasia (BPH) which affects 50% of men over the age of 50.

19 Mar 2014

Loyola urogynecologist receives 2014 Christina Manthos Mentoring Award from SWIU

Elizabeth Mueller, MD, MS, has been named a 2014 Christina Manthos Mentoring Award recipient by the Society of Women in Urology (SWIU). Dr. Mueller is the division director and the fellowship program director of Female Pelvic Medicine & Reconstructive Surgery at Loyola University Health System.

18 Mar 2014